(S)-2-Amino-3-{4-[4-(2,4-dioxothiazolidin-5-ylmethyl)-phenoxy]-phenyl}-propionic acid methyl ester hydrochloride | 872186-88-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-Amino-3-{4-[4-(2,4-dioxothiazolidin-5-ylmethyl)-phenoxy]-phenyl}-propionic acid methyl ester hydrochloride
• 英文别名: methyl (2S)-2-amino-3-(4-{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy}phenyl)propanoate hydrochloride；methyl (2S)-2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]propanoate;hydrochloride
• CAS: 872186-88-4
• 化学式: C₂₀H₂₀N₂O₅S*ClH
• 分子量: 436.916
• InChiKey: USGKBRMYSUMVLX-KHTASDDNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.84
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  133
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Novel diphenyl ether derivatives
  申请人：Nag Bishwajit

  公开号：US20050288341A1

  公开（公告）日：2005-12-29

  Novel diphenyl ether derivatives are provided that exhibit activity useful for reducing glucose, cholesterol, and/or triglyceride levels in plasma, and for treatment of obesity, inflammation, immunological diseases, autoimmune diseases, diabetes and disorders associated with insulin resistance.

  提供了新颖的二苯醚衍生物，具有降低血浆中葡萄糖、胆固醇和/或甘油三酯水平以及治疗肥胖、炎症、免疫性疾病、自身免疫性疾病、糖尿病和与胰岛素抵抗相关的疾病的有用活性。
• 5- [4- (4- (2 -AMINO- 2 -METHOXYCARBONYLETHYL) PHENOXY) BENZILIDENE]THIAZOLIDIN-2 , 4-DION E DERIVATIVES AND RELATED COMPOUNDS FOR REDUCING GLUCOSE, CHOLESTEROL AND TRIGLYCERIDE LEVELS IN PLASMA
  申请人：Bexel Pharmaceuticals Inc

  公开号：EP1848700A1

  公开（公告）日：2007-10-31
• SALTS OF (S)-2-AMINO-3-{4-[4-(2,4-DIOXO-THIAZOLIDIN-5-YLMETHYL)-PHENOXY]-PHENYL}-PROPIONIC ACID AND ITS METHYL ESTER AS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF OBESITY OR DIABETES
  申请人：Bexel Pharmaceuticals Inc

  公开号：EP1848700B1

  公开（公告）日：2015-12-30
• Novel MAO-A inhibitors
  申请人：Dey Debendranath

  公开号：US20090069313A1

  公开（公告）日：2009-03-12

  The present invention provides a new medical use for the compounds of the formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, as MAO-A inhibitors. Also included is a method for prophylaxis and treatment of mental disorders such as depression, in a mammal, comprising administering an effective amount of a compound of formula (I). These compounds are also effective in treating a disease, condition or disorder such as weight loss, obesity, bulimia, depression, bipolar disorders, psychoses, schizophrenia, behaviors, alcoholism, tobacco abuse, memory loss, Alzheimer's disease, dementia of aging, seizure disorders, epilepsy, attention deficit disorder, and Parkinson's disease, which is modulated by a cannabinoid receptor antagonist.
• US7521465B2
  申请人：——

  公开号：US7521465B2

  公开（公告）日：2009-04-21